Pharmaceutical company Biocon has settled the suit through a confidential settlement agreement with Celgene Corporation relating to patents for generic Revlimid drug, the company said in an exchange filing.

 “This is to inform you that Biocon Limited and its subsidiaries Biocon Pharma Limited and Biocon Pharma Inc. (“Biocon”) has entered into a confidential settlement agreement with Celgene Corporation (Celgene), a wholly-owned subsidiary of Bristol Myers Squibb (NYSE: BMY), relating to patents for REVLIMID (lenalidomide),” Biocon said in the filing. 

In May this year, Celgene Corporation had filed a complaint in the District of New Jersey against Biocon Pharma Inc. The action focussed on potential patent infringement regarding ten patents held by Celgene which would infringe upon by a potential generic drug created by Biocon.

The patents address methods for treating cancer, specifically multiple myeloma and related blood and bone marrow cancers. The patents resulted in a drug regimen specifically designed to treat these patients after bone marrow transplantation, under the name Revlimid.

On the other hand, Biocon had filed for approval from the US Food and Drug Administration (FDA).

Revlimid is a blood cancer drug with sales of US $ 12.1 billion for BMS in 2020.

Celgene alleged that the Biocon’s Abbreviated New Drug Application (ANDA) for the generic version of Revlimid (lenalidomide capsules) in the US to engage in the commercial manufacture, use, sale, offer for sale, or importation into the US will be before the expiration of the patents Celgene holds and approval of the same would result in infringement.